The death toll among Japanese citizens who have taken Johnson & Johnson’s subsidiary Janssen’s schizophrenia drug Xeplion has climbed to 21, from 17 on April 10, prompting the Japanese health ministry to order the manufacturer to warn patients about its risks. Although a causal link between Xeplion and the deaths has not been established, the health ministry ordered Janssen to revise its package insert, considering the unusually high number of deaths since the drug’s recent release.
I bet when the lawsuits roll in from the families of the dead Johnson & Johnson will simply use a small portion of profits to settle out of court, admitting no guilt .
Is this Xeplion named Invega Sustenna in North America?
Yes, one of the ways PhRMA fools people, is by using different names for the same drug, in different countries. This is beyond having a common generic chemical name for a drug, and a copyrighted trade name for the same drug. Now, (March 2017), there are ongoing lawsuits, which, as “Copy_cat” above suggests, will probably just be paid off by PhRMA, as a type of “business tax”. In the eyes of the Global Drugs Industry, *YOU* are an expendable human guinea pig, and of *NO* *VALUE* as an individual….. Sad *TRUTH*….
YES! According to the data they are both paliperidone palmitate.